CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...

For 20 years, this computational linguistics competition has inspired new generations of innovators in AI and language ...

Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection. Australia-based CSL picked ...

Exclusive licensing grants Lilly development and commercialization rights for clazakizumab beyond ESKD-related cardiovascular prevention, while CSL retains the ESKD cardiovascular events indication.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Once labeled "different" and misunderstood in school, Elon Musk stunned experts as a teen with record-breaking computer ...

Ord Minnett sees one as a buy and one to hold. CSL shares have come under heavy scrutiny recently. Investors have been exiting their positions in the company following its half year earnings results.

As AI systems began acing traditional tests, researchers realized those benchmarks were no longer tough enough. In response, nearly 1,000 experts created Humanity’s Last Exam, a massive 2,500-question ...

Researchers have developed new methods to test food for bacterial contamination that are faster and do not require expert ...

Feb 18 (Reuters) - Australia's CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co, granting it certain rights to develop and commercialise clazakizumab, ...

The CEO killing season is back after a decade of relative stability and while the reasons behind a raft of chief executive departures are varied, leading directors say there has never been a tougher ...

(Corrects headline to remove incorrect reference to CSL licensing Eli Lilly's clazakizumab) Feb 18 (Reuters) - Australia's CSL said on Wednesday it had entered into an exclusive licensing agreement ...